Curis, Inc. (NASDAQ:CRIS) was the target of a large drop in short interest in September. As of September 28th, there was short interest totalling 945,050 shares, a drop of 26.6% from the September 14th total of 1,286,680 shares. Currently, 3.5% of the company’s stock are sold short. Based on an average daily volume of 188,525 shares, the days-to-cover ratio is currently 5.0 days.
CRIS has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Curis from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a report on Wednesday, August 8th. Cowen reiterated a “buy” rating on shares of Curis in a report on Monday, August 6th. SunTrust Banks dropped their target price on shares of Curis to $8.00 and set a “buy” rating on the stock in a report on Friday, August 3rd. Finally, ValuEngine downgraded shares of Curis from a “buy” rating to a “hold” rating in a report on Monday, July 2nd. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Curis presently has an average rating of “Buy” and an average price target of $18.75.
Shares of CRIS opened at $1.89 on Friday. The firm has a market capitalization of $59.06 million, a P/E ratio of -1.05 and a beta of 1.11. Curis has a one year low of $1.36 and a one year high of $8.70. The company has a current ratio of 3.01, a quick ratio of 3.01 and a debt-to-equity ratio of 4.43.
Institutional investors and hedge funds have recently made changes to their positions in the stock. LMR Partners LLP bought a new position in Curis in the 2nd quarter worth $124,000. Paloma Partners Management Co bought a new position in shares of Curis during the 2nd quarter worth about $223,000. Finally, Millennium Management LLC bought a new position in shares of Curis during the 2nd quarter worth about $540,000. Hedge funds and other institutional investors own 33.49% of the company’s stock.
Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.
Further Reading: Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.